Nearest large city: MinneapolisSt. Paul
What $300,000 will buy: 4-bedroom, 2-bath 1920s bungalow with detached garage close to downtown
SLIDE SHOW: See Our Picks for 10 Great Places to Retire, 2017
Home to St. Olaf College and Carleton College, Northfield seamlessly blends town and gown. Retirees George and Linda Davis, 70, can vouch for that. Last year, they moved here from Moorhead, Minn., to be closer to their children in the Twin Cities, 45 miles to the north. Recently, the couple attended a presentation at Carleton about the theologian Reinhold Niebuhr with about 200 people in attendance. Half of them were college students and half were gray hairs like us, says Linda. I thought, You wont get that in every community.
day trading techniques: CGG(CGG)
- [By Lisa Levin]
CGG SA (ADR) (NYSE: CGG) shares shot up 32 percent to $7.15 after the company reported an agreement in principle on financial restructuring plan with main creditors and DNCA.
- [By Jonas Elmerraji]
First up is French oil service firm CGG Veritas (CGG)
. The Eurozone-based energy stock hasn’t exactly posted blockbuster performance in 2013, but investors who ignore CGG for the final stretch of the year could be making a big mistake. That’s because of a bullish technical pattern that’s emerging in shares right now.
CGG spent most of the last eight months looking anything but bullish. But an ascending triangle pattern is changing that. The pattern is formed by horizontal resistance to the upside at $26, and uptrending support to the below shares. Basically, as CGG bounces in between those two technical levels, it’s getting squeezed closer and closer to a breakout above $26. When that happens, traders have a buy signal.
The ascending triangle pattern in CGG Veritas isn’t exactly textbook. That’s because the setup is forming at the bottom of a downtrend, rather than in the middle of an uptrend – but it’s a mistake to get caught up on the textbook pictures of what trading patterns are supposed to look like. On a move through $26, the trading implications are just as actionable.
day trading techniques: Surgical Care Affiliates, Inc.(SCAI)
- [By Lisa Levin]
Surgical Care Affiliates Inc (NASDAQ: SCAI) shares were also up, gaining 16 percent to $56.55 after UnitedHealth Group Inc. (NYSE: UNH) disclosed that its unit agreed to acquire Surgical Care Affiliates for around $2.3 billion.
day trading techniques: Imprivata, Inc.(IMPR)
- [By Lisa Levin]
Shares of Imprivata Inc (NYSE: IMPR) got a boost, shooting up 31 percent to $19.01 as the company reached a definitive deal to be bought by an affiliate of Thoma Bravo, LLC, a private equity firm, for $544 million
day trading techniques: Benitec Biopharma Limited(BNTC)
- [By Lisa Levin]
Benitec Biopharma Ltd (ADR) (NASDAQ: BNTC) shares shot up 44 percent to $4.41. Benitec Biopharma disclosed that the key pre-clinical data on oculopharyngeal muscular dystrophy has been published in Nature Communications.
- [By Alex McGuire]
Here’s a list of the top 10 penny stocks to watch in March, which includes the biggest gainers last month…
Penny StockCurrent Stock PriceFebruary 2017 ReturnZosano Pharma Corp. (Nasdaq: ZSAN)$2.56+123.3%Bellerophon Therapeutics Inc. (Nasdaq: BLPH)$1.25+113.8%Peregrine Pharmaceuticals (Nasdaq: PPHM)$0.59+101.7%Galectin Therapeutics Inc. (Nasdaq: GALT)$1.79+91.9%Bioanalytical Systems Inc. (Nasdaq: BASI)$1.58+90.6%CymaBay Therapeutics Inc. (Nasdaq: CBAY)$3.50+89.8%Vermillion Inc. (Nasdaq: VRML)$2.56+86.3%Naked Brand Group Inc.(Nasdaq:NAKD)$2.16+76%Eyegate Pharmaceuticals Inc. (Nasdaq: EYEG)$2.63+73.9%Benitec Biopharma Ltd. (Nasdaq ADR: BNTC)$2.60+59.9%
The best-performing penny stock – Zosano Pharma Corp. – soared an incredible 123.3% from Feb. 1 to Feb. 28. To put those gains into perspective, that’s more than five times the S&P 500’s 23% climb in the last 12 months.
day trading techniques: Luxoft Holding, Inc.(LXFT)
- [By Steve Symington]
Luxoft Holding(NYSE:LXFT)announced strong fiscal fourth-quarter results on Monday, after the market closed. Similar to its modest post-earnings drop in February, shares of the software development specialist fell 3.6% on Tuesday as investors absorbed the news.
day trading techniques: Coherus BioSciences, Inc.(CHRS)
- [By Lisa Levin]
Coherus Biosciences Inc (NASDAQ: CHRS) shares shot up 23 percent to $13.70 after the company announced plans to raise up to $150 million in a private placement.
- [By Lisa Levin] Gainers Red Robin Gourmet Burgers, Inc. (NASDAQ: RRGB) shares rose 18.4 percent to $68.65 in pre-market trading as the company reported upbeat results for its first quarter. Jack in the Box Inc. (NASDAQ: JACK) shares rose 9.5 percent to $111.60 in the pre-market trading session after the company posted better-than-expected earnings for its second quarter. The company also disclosed that it has retained Morgan Stanley to evaluate potential alternatives for Qdoba. Coherus Biosciences Inc (NASDAQ: CHRS) rose 9.8 percent to $24.20 in pre-market trading. Coherus BioSciences disclosed that it prevailed in ‘135 IPR decision. Qiwi PLC (NASDAQ: QIWI) rose 8.1 percent to $21.49 in pre-market trading after reporting strong quarterly results. Korea Electric Power Corporation (ADR) (NYSE: KEP) shares rose 7.9 percent to $20.00 in pre-market trading after dropping 4.33 percent on Tuesday Target Corporation (NYSE: TGT) shares rose 7.5 percent to $58.60 in pre-market trading after the company reported stronger-than-expected results for its first quarter. AngloGold Ashanti Limited (ADR) (NYSE: AU) rose 4.3 percent to $11.71 in pre-market trading after falling 0.09 percent on Tuesday. Colgate-Palmolive Company (NYSE: CL) rose 4.1 percent to $74.53 in pre-market trading after the NY Post reported that the company might be up for sale for $100 per share. Harmony Gold Mining Co. (ADR) (NYSE: HMY) rose 4 percent to $2.35 in pre-market trading after declining 1.74 percent on Tuesday. Core Laboratories N.V. (NYSE: CLB) rose 3.6 percent to $109.00 in pre-market trading after gaining 0.39 percent on Tuesday. Clovis Oncology Inc (NASDAQ: CLVS) rose 3.2 percent to $51.15 in pre-market trading. JP Morgan upgraded Clovis Oncology from Neutral to Overweight.
Find out what's going on in today's market and bring any questions you have to Benzinga's PreMarket Prep.
- [By Ben Levisohn]
Today,Coherus BioSciences (CHRS) lost a patent case with AbbVie (ABBV) that would have allowed for a generic version of Humira. Citigroup’s Andrew Baum and Peter Verdult have the details:
Agence France-Presse/Getty Images
The Patent Trial and Appeal Boardjust announced that CHRSs IPR on the 166 Humira formulation patent was not instituted. We remind investors that Amgens IPR on the same 157 and 158 formulation patents were also not instituted. Any at risk launch on a formulation that potentially infringes 166, 157 or 158 would seem unlikely and carries a high risk thatAbbVie would attain a preliminary injunction. It is not clear whether either company could attempt launch with a formulation that does not infringe the patent estate. We note that Sandoz has uniquely not filed any IPR on any biosimilars. Sandoz has not announced the FDA has accepted their filing for their biosimilar adalimumab…We anticipate that the perceived historic relationship of the immunogenicity of Humira as it relates to dose stretching will form a key debate in the ongoing PTAB case…
Following the decision of the PTAB not to institute CHRS IPR on the 166 Humira formulation patent, we continue to anticipate that first likely launch of biosimilar adalimumab (Humira) in the US will be delayed until 2020, in line with our published forecasts and biosimilar model. We anticipate the open IPR hearings for the 135 dosing patent on Humira (filed by Boehringer and Coherus) to begin in Feb 2017 with the ruling in May. We rateAbbVie a Buy. We continue to prefer BUY rated Bristol-Myers Squibb (BMY), Eli Lilly (LLY) among the US names.
Shares of AbbVie have climbed 5.6% to $59.18 at 3:05 p.m. today, while Coherus BioSciences has tumbled 11% to $25.18,Bristol-Myers Squibb has gained 3% to $52.56, andEli Lilly has risen 1.7% to $73.70.